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In-vivo assessment of in-vitro killing patterns
of Pseudomonas aeruginosa
A. U. Gerber and C. Feller-Segessenmann
Department of Medicine, Inselspital, and Institute of Medical Microbiology,
University of Bern, Switzerland
Time-kill curves of Pseudomonas aeruginosa exposed to gentamicin or ticarcilhn in
vitro were correlated with time-kill curves obtained with various dosage schedules of
the same study drugs in granulocytopenic mice. An instantaneous, fast and drug-
dependent killing pattern was found in vitro with gentamicin. This pattern
corresponded to bacterial killing m vivo which was clearly dependent on peak drug
levels. In contrast, slow bacterial killing with little relationship to concentration was
found in vitro with ticarcilhn and proved to correlate with an antibacterial effect in
vivo seen at trough levels. We conclude that in-vitro time-kill curves of antimicrobial
agents may be predictive for optimizing dosage regimens in vivo.
Introduction
The in-vitro activity of an antibiotic can be well established in time-kill curves as
obtained by exposure of the test bacteria to various concentrations of drug. In similar
experiments, the regrowth pattern of bacteria can be studied in vitro after short
exposure of the organisms to the study drug. Using such technique, Bundtzen et al.,
(1981) and Gerber & Craig (1981) have shown that exposure of various Gram-negative
bacteria to inhibitors of protein- or nucleic acid-synthesis is followed by a persistent
post-antibiotic effect (PAE); i.e. a persistent suppression of bacterial growth upon
removal of the drug. In contrast, virtually no PAE was found after exposure of Gram-
negative rods to /Mactam drugs.
Little is known about how killing and regrowth patterns observed in vitro relate to
antimicrobial activity of antibiotics in vivo. In the present study, therefore, experiments
were devised to establish time-kill curves of the same pairs of drug and organism not
only in vitro but also in vivo. A hypothesis was proposed that in-vivo efficacy of an
antimicrobial agent is related to peak plasma levels whenever a fast bactericidal drug
effect and a PAE are found in vitro, whereas slow bacterial killing and absence of a
PAE in vitro indicate that in-vivo antimicrobial activity depends not on peak- but
mainly on trough drug levels.
Materials and methods
Pseudomonas aeruginosa ATCC 27853 was the main study organism. Two clinical
isolates of Ps. aeruginosa were included in confirmatory experiments. Ticarcillin
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(Beecham) and gentamicin (Shering, U.S.A.) were the drugs used. In-vitro time-kill
curves were constructed after exposure of the organisms to various concentrations of
drug in Mueller-Hinton broth supplemented with Ca++ and Mg++ according to
Stratton & Reller (1977). The number of colony-forming units (cfu) was determined by
plating serial dilutions of appropriate culture samples onto tryptic soy agar plates.
Methods for in-vivo studies have been described by Gerber, Craig & Brugger (1983).
Agranulocytic (cyclophosphamide treated) mice were used. On the day of the
experiment, mice were injected with 107 cfu of the organisms in the thigh muscle. Two
hours later treatment was started with sc injections of the study drug. In some
experiments mice were randomized and treated with either a 1-h or a 3-h regimen such
that identical total amounts of injected drug resulted in both groups after 3, 6, 9 and
12 h of treatment. Blood was drawn from the retro-orbital sinus of all mice, and
plasma drug levels were determined using a biological method (Bacillus subtilis as
indicator organism). Antimicrobial activity was assessed by viable counts in
homogenized thighs of killed animals, and time-kill curves were constructed.
Results
Killing patterns of Ps. aeruginosa in vitro
Time-kill curves of Ps. aeruginosa ATCC 27853 obtained in vitro with various
concentrations of gentamicin and ticarcillin are shown in Figure 1. A substantial
difference between the two drugs was found regarding the time course of the
bactericidal effect. Killing by gentamicin was fast, very much concentration-dependent,
but followed by bacterial break-through growth. On the other hand, ticarcillin needed
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Figure 1. In-viiro time course of the bactericidal effects of gentamicin (a) and ticarallin (b) on
Ps. aeruginosa ATCC 27853 in calcium- and magnesium-supplemented MHB. Standard MICs (MBCs) for
6 x 10' organisms were 2 (8) and 32 (32)mg/l of gentamicin and ticarallin, respectively O Control- •
half-fold MIC; A , two-fold MIC, • , ten-fold MIC. ' '
Pseudomonas killing patterns in vivo 203
several hours to exert a 99% bactericidal effect which was poorly concentration-
dependent No break-through growth was observed at levels greater than the MICs of
ticarcillin.
Comparative killing patterns in vivo
Killing patterns similar to those obtained in vitro were observed with high dose
treatment of Ps. aeruginosa ATCC 27853 in the thigh infection model using
granulocytopenic mice (Figure 2). Gentamicin resulted in > 90% bacterial killing in
the first 6 h of treatment, but a significant break-through growth was observed
thereafter, although treatment continued and plasma levels far above the MIC were
obtained, at least intermittently. The bactericidal effect of ticarcillin on the other hand
was slow and bacterial break-through growth did not occur up to 24 h of high dose
treatment.
Additional experiments were performed with lower doses of drug to see the effect of
dosage schedule on antipseudomonal activity in vivo (Figures 3 and 4).
Importance of dosage schedules of gentamicin
Experiments with gentamicin (Figure 3) clearly revealed the key importance of peak
levels for the antimicrobial effect of this drug. By 3 h of treatment, a single injection of
15 mg/kg of gentamicin (resulting in peak plasma levels of approximately 20 mg/1) was
clearly more effective than the same total amount of drug subdivided in three
fractional doses injected every hour and resulting in peak plasma levels of
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Figure 2. Comparative in-wvo killing patterns of a 3-h schedule of gentamicin (a), and ticarcillin (b\
on Ps aerugmosa ATCC 27853 (granulocytopenic mice) The plasma kinetics of a single dose of gentamicin
and ticarcillin are shown on a logarithmic scale in the (c) and (d) Each point represents the mean value
±4.D of three mice See Figure I for MIC and MBC-values
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FIgnre 3. Importance of dosage schedules of gentamicin on Ps aeruginosa ATCC 27853 in vivo
(granulocytopenic mice)
The effects of two 1-h regimens are compared to two 3-h regimens. Identical total amounts of drug had
been injected in comparatively treated mice after 3, 6, 9, and 12 h. O. Control; A, 167 mg/kg q 1 h; A,
5 mg/kg q 3 h, • , 5 mg/kg q 1 h, ©, 15 mg/kg q 3 h.
approximately 6-8 mg/1. Break-through growth could not be prevented by either of the
two gentamicin dosage regimens.
Importance of dosage schedules of ticarcillin
The time course of the antipseudomonal effect of ticarcillin and the impact of dosage
intervals of this drug were studied in granulocytopenic mice infected simultaneously
with two clinical isolates of Ps. aeruginosa which differed substantially in virulence and
susceptibility to ticarcillin (Figure 4). In contrast to strain E 29/2, strain 14974 was
unable to grow in the thigh muscle of non-granulocytopenic mice. In vitro as well as in
granulocytopenic mice strain 14974 multiplied slower than strain E 29/2. The colonies
formed by the two strains on agar plates (small for strain 14974, larger and mucoid for
strain E 29/2) could easily be distinguished.
Identical inocula of the two strains were injected into left and right thighs,
respectively, of the same mice. Treatment was started 2 h later at a 1 h vs. a 3 h
schedule, using identical total amounts of drug in both groups of mice treated. Against
both Ps. aeruginosa strains tested the only effect of the 3 h regimen was to slow down
bacterial growth. However, a complete bacteriostatic or bactericidal effect was not
obtained, although peak plasma levels exceeded by at least two-fold the MIC for strain
E 29/2 and by 64-fold the MIC for strain 14974. One hour injections of fractional
doses of the same total amount of ticarcillin proved to be significantly more efficaceous
against both strains tested despite three-fold lower peak plasma levels which, for strain
E 29/2, did not even reach the MIC. Thus, the activity of ticarcillin was mainly
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Figure 4. Importance of dosage schedules of Ucaraliin on activity against two clinical isolates of
Ps aerugmosa (a) 14974, MIC 1 mg/1; (b) E 29/2, MIC 32 mg/1 Peak plasma levels of Ucaraliin and
presumptive kinetics of the two dosage regimens is shown in (c). O, Control; A. 90 mg/kg q 3 h; # , 30 mg/kg
I h Four mg/1 of ticarcilhn was the lower limit of detectability in the biological assay used Identical total
amounts of drug had been injected in both regimens by 3 and 6 h of treatment
dependent on constant presence of the drug rather than on peak levels far in excess of
the MIC.
Discussion
Our experiments clearly demonstrate the difference between gentamicin and ticarcillin
regarding the time course of their pharmacological response in vitro as well as in vivo.
In vivo the antipseudomonal activity of gentamicin proved to be dependent on peak
plasma levels. This finding reflected the dose-response curve observed with gentamicin
in vitro which showed that increasing concentrations of gentamicin increased both
absolute bacterial killing and the speed of killing. In addition, Bundtzen et al. (1981)
have demonstrated a PAE of gentamicin on Ps. aeruginosa which lasted 1-6—2-6 h. This
effect may thus cover, at least in part, the period of sub-MIC plasma levels between
doses and prevent early bacterial regrowth during that phase of treatment In
conclusion, a gentamicin-type response, i.e. peak-dependent killing and a PAE, may
well indicate an advantage in vivo of high dose, long interval treatment over a low dose,
short interval regimen of any antimicrobial agent. This interpretation of the present
data is in full agreement with our previous work (Gerber et al. 1983) and with the
results of recent investigations by Powell, Thompson & Luthe (1983) who found once
daily doses of aminoglycosides to be more effective than more frequent injections.
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Interestingly, in those studies once daily dosing of aminoglycosides was also less toxic
than the conventional 8 h schedule.
Our in-vivo results with ticarcillin were not surprising. Bacterial killing in vitro was
slow and showed a poor correlation with concentration. High peak levels greatly
exceeding the MIC seem to be of little value in vivo. On the other hand, the half-life of
ticarcillin in mice was shorter than 20 min. It is therefore possible that the action time
was just too short to exert any bactericidal effect. Since the half-life in man is
considerably longer than in mice, a drug showing a response similar to that of
ticarcillin might be underestimated when investigated in mice (Gerber et al., 1983).
However, it should be remembered that ticarcillin clearly lacks a PAE on
Ps. aeruginosa in vitro (Bundtzen et al., 1981). Therefore, it is logical to conclude that
any antibiotic showing a response like that of ticarcillin does require super-MIC drug
levels at all times in order to exert its maximal antimicrobial activity in vivo. This
activity must therefore be associated with trough plasma levels.
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